NCT01270997View on ClinicalTrials.gov

Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Etanercept

Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks

BIOLOGICAL

Etanercept

Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks

Trial Locations (1)

133-792

Hospetal for Rheumatic Diseases Hanyang University Medical Center, Seoul

Sponsors

Lead Sponsor

Hanwha Chemical
All Listed Sponsors
lead

Hanwha Chemical

INDUSTRY